Drug Trial Radar · NCT05403541
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
233
Actual
Start
Jun 27, 2022
Primary completion
Jan 10, 2025
Study completion Aug 7, 2026
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint will be assessed by change in the myasthenia gravis activities of daily living (MG- ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previously treated with batoclimab will be re-randomized to stay on batoclimab (340 mg SC QW or 340 mg SC every two weeks) or receive placebo treatment. The secondary endpoint of maintenance of efficacy will be assessed by change in the MG- ADL score in AChRAb+ participants. Participants demonstrating a response to batoclimab during either Period 1 or 2 may enter the long-term extension (Period 3). Participants who complete Period 3 are eligible to participate in Period 4 (Optional Long-Term extension) according to their treatment assignment in Period 3.
Conditions
- Generalized Myasthenia Gravis
Interventions
Batoclimab 680 mg SC weeklyDrug
Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Batoclimab 340 mg SC weeklyDrug
Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Matching Placebo SCDrug
Placebo
Batoclimab 340 mg SC bi-weeklyDrug
Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score in acetylcholine receptor (AChR) Ab seropositive (AChRAb+) participantsTime frame: Baseline (Day 1) to Week 12
Locations
93 sites in 16 countries. Site status is shown where the registry gives one.
Site Number -1022
Phoenix, Arizona
Site Number -1029
Scottsdale, Arizona
Site Number -1002
Carlsbad, California
Site Number -1009
Irvine, California
Site Number - 1012
Olive View, California
Site Number -1032
San Francisco, California
Site Number - 1027
Aurora, Colorado
Site Number - 1025
New Haven, Connecticut
Site Number -1007
Clearwater, Florida
Site Number -1010
Maitland, Florida
Site Number - 1020
Miami, Florida
Site Number - 1019
Orlando, Florida
Site Number - 1028
Port Charlotte, Florida
Site Number - 1015
Tampa, Florida
Site Number -1011
Fairway, Kansas
Site Number -1003
Lexington, Kentucky
Site Number -1013
East Lansing, Michigan
Site Number - 1024
Minneapolis, Minnesota
Site Number - 1021
Buffalo, New York
Site Number - 1018
Chapel Hill, North Carolina
Site Number - 1008
Durham, North Carolina
Site Number -1004
Cleveland, Ohio
Site Number -1006
Portland, Oregon
Site Number - 1023
Philadelphia, Pennsylvania
Site Number - 1026
Memphis, Tennessee
Site Number -1001
Austin, Texas
Site Number -1016
Dallas, Texas
Site Number - 1034
Houston, Texas
Site Number - 1014
Round Rock, Texas
Site Number -1005
Charlottesville, Virginia
Site Number - 5002
Buenos Aires, Argentina
Site Number - 5001
Buenos Aires, Argentina
Site Number - 5003
Rosario, Argentina
Site Number - 5501
Ribeirão Preto, Brazil
Site Number- 5503
Rio de Janeiro, Brazil
Site Number - 2003
Vancouver, British Columbia, Canada
Site Number - 2002
Toronto, Ontario, Canada
Site Number - 2004
Montreal, Quebec, Canada
Site Number -8002
Tbilisi, Georgia
Site Number -8004
Tbilisi, Georgia
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.